IBA offers worldwide PET research community investigational radiopharmaceutical

Ion Beam Applications (IBA) announced that its US subsidiary, Eastern Isotopes, Inc. has begun distributing Iodine-124 (MIBG), an analogue of a biogenic amine precursor, norepinephrine. MIBG has been widely used in its radiolabbeled forms (usually I-123 or I-131) for the evaluation of the cardiac sympathetic nervous system and the diagnosis, treatment planning and radiotherapy of various neuroendocrine malignancies.  IBA expects that I-124 MIBG may be useful for researchers evaluating other types of patients.  The FDA has not evaluated it.

IBA, headquartered in Belgium provides radiopharmaceuticals, notably in the field of Positron Emission Tomography (PET).

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.